Cargando…

Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer

Abnormal expression and function of chromatin regulators results in the altered chromatin structure seen in cancer. The chromatin regulator CTCF, its cofactor CHD8, and antagonistic paralogue BORIS have wide-ranging effects on gene regulation. Their concurrent expression and regulation was examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Damaschke, Nathan A., Yang, Bing, Blute, Michael L., Lin, Chee Paul, Huang, Wei, Jarrard, David F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309256/
https://www.ncbi.nlm.nih.gov/pubmed/25499215
http://dx.doi.org/10.1016/j.neo.2014.10.003
_version_ 1782354666205478912
author Damaschke, Nathan A.
Yang, Bing
Blute, Michael L.
Lin, Chee Paul
Huang, Wei
Jarrard, David F.
author_facet Damaschke, Nathan A.
Yang, Bing
Blute, Michael L.
Lin, Chee Paul
Huang, Wei
Jarrard, David F.
author_sort Damaschke, Nathan A.
collection PubMed
description Abnormal expression and function of chromatin regulators results in the altered chromatin structure seen in cancer. The chromatin regulator CTCF, its cofactor CHD8, and antagonistic paralogue BORIS have wide-ranging effects on gene regulation. Their concurrent expression and regulation was examined in benign, localized, and metastatic prostate cancer (PCa) arrays with extended follow-up using an automated quantitative imaging system, VECTRA. Epithelial staining was quantified and compared against a range of clinicopathologic variables. CHD8 expression was decreased in HGPIN, localized, and metastatic PCa compared to benign (P < .001). CHD8 promoter hypermethylation, assessed by Quantitative Pyrosequencing, occurred in over 45% of primary cancers in this population as well as the TGCA database. Treatment of cell lines with the demethylating agent 5-Aza-2′-deoxycytidine reinduced expression. An interesting dichotomy for CHD8 was observed within primary cancers, with higher nuclear protein expression associated with adverse clinical outcomes including extracapsular extension (P = .007), presence of metastases (P = .025) and worse PSA-recurrence free survival (P = .048). CHD8 outperformed Gleason score and predicted biochemical failure within intermediate grade prostate cancers. The BORIS/CTCF expression ratio increased in localized (P = .03) and metastatic PCa (P = .006) and was associated with higher Gleason score (P = .02), increased tumor volume (P = .02) and positive margins (P = .04). Per cell heterogeneity of expression revealed all protein expression to be more heterogeneous in cancerous tissue (both P < .001), especially high grade (P < .01). In the first detailed analysis in cancer, a marked loss of CHD8 expression and increased BORIS/CTCF ratio indicate frequent disruption of CTCF and its effector genes in PCa.
format Online
Article
Text
id pubmed-4309256
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-43092562015-01-30 Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer Damaschke, Nathan A. Yang, Bing Blute, Michael L. Lin, Chee Paul Huang, Wei Jarrard, David F. Neoplasia Article Abnormal expression and function of chromatin regulators results in the altered chromatin structure seen in cancer. The chromatin regulator CTCF, its cofactor CHD8, and antagonistic paralogue BORIS have wide-ranging effects on gene regulation. Their concurrent expression and regulation was examined in benign, localized, and metastatic prostate cancer (PCa) arrays with extended follow-up using an automated quantitative imaging system, VECTRA. Epithelial staining was quantified and compared against a range of clinicopathologic variables. CHD8 expression was decreased in HGPIN, localized, and metastatic PCa compared to benign (P < .001). CHD8 promoter hypermethylation, assessed by Quantitative Pyrosequencing, occurred in over 45% of primary cancers in this population as well as the TGCA database. Treatment of cell lines with the demethylating agent 5-Aza-2′-deoxycytidine reinduced expression. An interesting dichotomy for CHD8 was observed within primary cancers, with higher nuclear protein expression associated with adverse clinical outcomes including extracapsular extension (P = .007), presence of metastases (P = .025) and worse PSA-recurrence free survival (P = .048). CHD8 outperformed Gleason score and predicted biochemical failure within intermediate grade prostate cancers. The BORIS/CTCF expression ratio increased in localized (P = .03) and metastatic PCa (P = .006) and was associated with higher Gleason score (P = .02), increased tumor volume (P = .02) and positive margins (P = .04). Per cell heterogeneity of expression revealed all protein expression to be more heterogeneous in cancerous tissue (both P < .001), especially high grade (P < .01). In the first detailed analysis in cancer, a marked loss of CHD8 expression and increased BORIS/CTCF ratio indicate frequent disruption of CTCF and its effector genes in PCa. Neoplasia Press 2014-12-09 /pmc/articles/PMC4309256/ /pubmed/25499215 http://dx.doi.org/10.1016/j.neo.2014.10.003 Text en © 2014 Neoplasia Press, Inc. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Article
Damaschke, Nathan A.
Yang, Bing
Blute, Michael L.
Lin, Chee Paul
Huang, Wei
Jarrard, David F.
Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer
title Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer
title_full Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer
title_fullStr Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer
title_full_unstemmed Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer
title_short Frequent Disruption of Chromodomain Helicase DNA-Binding Protein 8 (CHD8) and Functionally Associated Chromatin Regulators in Prostate Cancer
title_sort frequent disruption of chromodomain helicase dna-binding protein 8 (chd8) and functionally associated chromatin regulators in prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309256/
https://www.ncbi.nlm.nih.gov/pubmed/25499215
http://dx.doi.org/10.1016/j.neo.2014.10.003
work_keys_str_mv AT damaschkenathana frequentdisruptionofchromodomainhelicasednabindingprotein8chd8andfunctionallyassociatedchromatinregulatorsinprostatecancer
AT yangbing frequentdisruptionofchromodomainhelicasednabindingprotein8chd8andfunctionallyassociatedchromatinregulatorsinprostatecancer
AT blutemichaell frequentdisruptionofchromodomainhelicasednabindingprotein8chd8andfunctionallyassociatedchromatinregulatorsinprostatecancer
AT lincheepaul frequentdisruptionofchromodomainhelicasednabindingprotein8chd8andfunctionallyassociatedchromatinregulatorsinprostatecancer
AT huangwei frequentdisruptionofchromodomainhelicasednabindingprotein8chd8andfunctionallyassociatedchromatinregulatorsinprostatecancer
AT jarrarddavidf frequentdisruptionofchromodomainhelicasednabindingprotein8chd8andfunctionallyassociatedchromatinregulatorsinprostatecancer